Presented by Medscape Oncology, this activity is designed for continuing medical education (CME) credits. Moderated by Dr. Brian G.M. Durie (Chairman of the Board, the International Myeloma Foundation, and Multiple Myeloma Specialist, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles), the sections of this activity feature the following myeloma specialists:
- Dr. Rafat Abonour, MD, (Professor of Medicine, Indiana University School of Medicine, Indianapolis)
- Beth Faiman, PhD, CNP, Nurse Practitioner (Multiple Myeloma Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland)
- Thomas Martin, MD (Clinical Professor of Medicine, Associate Director, Myeloma Program, University of California, San Francisco Medical Center, San Francisco)
- Joseph Mikhael, MD (Professor of Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, City of Hope Cancer Center, and Chief Medical Officer, International Myeloma Foundation)
- Robert A. Vescio, MD, (Medical Director, Multiple Myeloma and Amyloidosis Program, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles)
To earn these CME credits,
1. Register for free at Medscape.org.
2. Login to your Medscape account.
3. Enter this link into your browser: https://www.medscape.org/viewarticle/919841?src=acdmpart_imf_919841
4. View these virtual courses in their entirety.
5. Complete CME/ABIMMOC credit activities.
Continuous Treatment of Transplant-Ineligible Patients
Learn about the role of maintenance therapy in transplant-ineligible patients with multiple myeloma
Brian Durie, MD; Joseph Mikhael, MD
After Transplant: The Role of Maintenance With or Without Prior Consolidation
Join the experts as they discuss the role of continuous therapy after transplant and consolidation
Brian Durie, MD; Robert Vescio, MD
Selecting Myeloma Maintenance Therapy for High-Risk Patients
Learn about the best practices for identifying appropriate maintenance therapy for high-risk multiple myeloma
Brian Durie, MD; Thomas Martin, MD
Multiple Myeloma Maintenance Therapy: How Long Do I Treat?
Learn with the experts as they discuss how to define the optimal length of maintenance therapy for multiple myeloma
Brian Durie, MD; Rafat Abonour, MD
Management of Adverse Events Associated With Maintenance Therapy
Gain insight into prevention and intervention for maintenance therapy-related toxicity
Brian Durie, MD; Beth Faiman, PhD
Key Takeaways and Future Directions
Join Dr Durie as he summarizes key highlights from the program
Brian Durie, MD
This activity is intended for hematology/oncology specialists, nurses, and pharmacists.
The goal of this activity is to increase the knowledge and competence of hematologists/oncologists and other clinicians who care for patients with multiple myeloma in the areas of treatment selection for transplant-ineligible patients, maintenance therapy, and management of therapy-related adverse events.
Upon completion of this activity, participants will have increased knowledge regarding the
- Treatment options, including duration of treatment, for patients with multiple myeloma (MM) after autologous stem cell transplant
- Best practices among members of the care team to optimize communication and coordination of patient care
Participants will also have greater competence related to
- Selecting optimal therapy for a newly diagnosed, transplant-ineligible patient with MM based on individual patient factors
- Monitoring for, identifying, and treating common therapy-related adverse events in patients with MM receiving consolidation or maintenance therapy